Experimental lung cancer vaccine trial halted early

NCT ID NCT04432207

Terminated Disease control Sponsor: Imugene Limited Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested an experimental immunotherapy called IMU-201 (PD1-Vaxx) in 24 adults with advanced non-small cell lung cancer. The treatment was given alone or combined with another immunotherapy drug (atezolizumab) and sometimes chemotherapy. The goal was to check safety and find the right dose. However, the study was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IMU-201 (PD1-Vaxx), a vaccine-like immunotherapy that trains the immune system to target PD-1
What this could lead to: If it works, this could offer a new way to control advanced lung cancer by helping the immune system attack cancer cells.
What could go wrong: This was a very early (Phase 1) trial that was terminated, so results are limited. The approach is still experimental and may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung adenocarcinoma lung large cell carcinoma non-small cell lung carcinoma non-small cell squamous lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOCARCINOMA LUNG LARGE CELL CARCINOMA LUNG NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER STAGE IIIB NON-SMALL CELL LUNG CANCER STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Cabrini Malvern Hospital

Melbourne, Victoria, 3000, Australia
Chris O'Brien Lifehouse

Camperdown, New South Wales, 2050, Australia
Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Macquarie University

Macquarie, New South Wales, 2109, Australia
Mayo Clinic

Phoenix, Arizona, 85054, United States
Ohio State University Medical Center

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.